uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma

Abstract

BACKGROUND:The aim of the current study was to report the results of 7422 uCyt1/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma. METHODS: Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt1/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt1/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt1/ImmunoCyt and cytology analyses were performed. RESULTS: Of the 7422 uCyt1/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt1/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt1/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt1/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system). CONCLUSIONS: On the basis of their 9-year experience, the authors confirm the value of uCyt1/ImmunoCyt and cytology analyses in the follow-up of patients with non-muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392-7.

Peptide-Conjugated Glass Slides for Selective Capture and Purification of Diagnostic Cells: Applications in Urine Cytology

“…Meanwhile, ICC can have a higher sensitivity than cytology for low-grade cancers (24, 25). As a result, the more expensive ICC- and FISH-based tests are commonly used to aid in the evaluation of epithelial cells deposited on slides.…”

Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer

“…6 Tetu et al showed that uCyt1 in combination with urinary cytology increased the sensitivity for the detection of BC up to 100%. The test tags mucin glycoprotein and carcinoembryonic antigen, both frequently expressed in urothelial cancer cells, with green and red fluorescence.…”

“…The test tags mucin glycoprotein and carcinoembryonic antigen, both frequently expressed in urothelial cancer cells, with green and red fluorescence. 6 Tetu et al showed that uCyt1 in combination with urinary cytology increased the sensitivity for the detection of BC up to 100%. Other reports on the sensitivity of uCyt1 as a single diagnostic measure range from 53% to 100% with specificities ranging from 64 to 95%, respectively.…”

“…Comparison of AUC curves in group R2 for different cut offs represents an adjunct to conventional urinary cytology using two fluorescence labeled tumor associated antigens, and has proven to optimize cell based urine BC diagnosis in prior studies 6,7. Since the recommended interpretation algorithm is containing numeric and quali-tative evaluation of luminescent cells, different approaches of classifying these luminescent cells as positive are conceivable, leading to aberrant positive and negative test results.…”

Clinical Use of the ImmunoCyt/uCyt+ and Fluorescence in Situ Hybridisation (FISH) Tests for Urothelial Carcinomas

“…In particolare, Messing riporta una sensibilità per il carcinoma in situ (cis) del 100%, dato poi confermato da Têtu e Mian (11,12). Il valore predittivo negativo dell'ImmunoCyt/uCyt+ da solo e in combinazione è risultato del 93-95%, nei diversi studi (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). Questi risultati, ormai confermati negli anni da numerosi studi sia in Nord America che in Europa, dimostrano la sicurezza della combinazione ImmunoCyt/uCyt+ con la citologia nei protocolli di sorveglianza.…”